2200 Research Blvd, Suite 550
44 articles with NEOIMMUNETECH, INC
NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients
HyLeukin-7 is an immunotherapeutic drug candidate designed to induce T cell proliferation and help the body fight serious disease.
NeoImmuneTech Strengthens Senior Management with the Appointment of NgocDiep Le, M.D., Ph.D., as Chief Medical Officer
NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, today announced the appointment of NgocDiep (‘Diep’) Le, M.D., Ph.D., as Chief Medical Officer (CMO)
NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.
NeoImmuneTech, Inc. announced today the initiation of its first U.S. clinical trial.
NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
NeoImmuneTech have entered into an agreement with Roche to enable studies of a combination treatment in three advanced high-risk skin cancer types.